Concetta Elisa Onesti
Concetta Elisa Onesti
Unknown affiliation
Verified email at uniroma1.it
TitleCited byYear
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ...
Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013
1502013
The use of bevacizumab in non-small cell lung cancer: an update
S Lauro, CE Onesti, R Righini, P Marchetti
Anticancer research 34 (4), 1537-1545, 2014
672014
Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know
C D'ANTONIO, A Milano, R Righini, CE Onesti, M Bassanelli, R Falcone, ...
Anticancer Research 34 (10), 5241-5250, 2014
192014
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer
A Romiti, CE Onesti, M Roberto, V Barucca, S Tomao, C D’Antonio, ...
Medical Oncology 32 (3), 54, 2015
182015
High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: a case series and the state of art
R Falcone, M Roberto, C D’Antonio, A Romiti, A Milano, CE Onesti, ...
Digestive and Liver Disease 48 (12), 1503-1505, 2016
162016
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ...
Oncotarget 8 (59), 99336, 2017
142017
Precision medicine for metastatic breast cancer.
AF Deluche E, Onesti E
Am Soc Clin Oncol Educ Book 35, e2-e7, 2015
142015
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer
M Roberto, A Romiti, CE Onesti, C D’Antonio, A Milano, R Falcone, ...
Anti-cancer drugs 27 (2), 106-111, 2016
122016
Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure
CE Onesti, A Romiti, M Roberto, R Falcone, P Marchetti
Expert review of anticancer therapy 15 (10), 1183-1198, 2015
92015
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer
A Romiti, M Roberto, C D’antonio, CE Onesti, V Barucca, A Milano, ...
Anti-cancer drugs 27 (10), 1044-1049, 2016
82016
Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival
M Roberto, A Botticelli, L Strigari, M Ghidini, CE Onesti, M Ratti, I Benzoni, ...
Medical Oncology 35 (7), 111, 2018
62018
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
F Mazzuca, CE Onesti, M Roberto, M Di Girolamo, A Botticelli, P Begini, ...
Oncotarget 9 (39), 25714, 2018
62018
Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice
A Milano, F Mazzetta, S Valente, D Ranieri, L Leone, A Botticelli, ...
Analytical Cellular Pathology 2018, 2018
62018
Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
MF Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B ...
PLoS One 11 (9), e0163105, 2016
62016
Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report
M Occhipinti, R Falcone, CE Onesti, P Marchetti
Drug safety-case reports 5 (1), 12, 2018
52018
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine
M Roberto, A Romiti, A Botticelli, F Mazzuca, L Lionetto, G Gentile, I Paris, ...
European journal of clinical pharmacology 73 (2), 157-164, 2017
52017
PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy?
B Cerbelli, A Pernazza, A Botticelli, L Fortunato, M Monti, P Sciattella, ...
BioMed research international 2017, 2017
52017
Gastric metastases from testicular cancer: case report and review of literature
S Lauro, R Righini, CE Onesti, E Pucci, A Bramini, P Marchetti
Journal of gastrointestinal cancer 45 (1), 22-24, 2014
52014
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient
A Botticelli, CE Onesti, L Strigari, M Occhipinti, FR Di Pietro, B Cerbelli, ...
Anti-cancer drugs 28 (5), 551-556, 2017
42017
Pharmacogenetic approach to toxicity in breast cancer patients treated with taxanes
S Angelini, A Botticelli, CE Onesti, R Giusti, V Sini, V Durante, L Strigari, ...
Anticancer research 37 (5), 2633-2639, 2017
42017
The system can't perform the operation now. Try again later.
Articles 1–20